arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Unicycive Therapeutics, Inc.

UNCY

$5.07 ▲ +0.04 (+0.70%) at close

7 Visible periods

22 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Unicycive Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $80.5M

Dividend Yield —

Revenue Growth None

Op. Margin —

ROIC -77.2% ↗

FCF / Share $-1.97 ↗

Trailing P/E —

Price / Book 3.7x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$675.00K

↓ -29.0% —

Net Income Profit after all expenses

$-26.55M

↑ +27.7% —

FCF / Share Free cash flow per share

$-1.97

↑ +53.9% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	—	—	-29.0% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-463%)	—	—	—	—
EPS Growth YoY (%)	70.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-341.4% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-6.7% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-39.5% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-218.5% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	27.7% Excellent ↑ Excellent Improving Year-over-year change in net income	-20.2% Weak ↑ Weak Improving Year-over-year change in net income	-69.1% Weak ↑ Weak Improving Year-over-year change in net income	-80.3% Weak Weak Year-over-year change in net income	-342.4% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	53.9% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-473.6% Weak ↓ Weak Declining Year-over-year change in free cash flow	28.3% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-109.4% Weak Weak Year-over-year change in free cash flow	-189.2% Weak Weak Year-over-year change in free cash flow	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
FCF / Net Income (x)	1.18x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.60x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.58x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.64x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-77.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-341.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	430.9% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	3060.3% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-43.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	59.7% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-60.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-101.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-146.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-640.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-47.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-990.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-87.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-686%)	—	—	—	-60.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-505%)	84.8% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+465%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Interest Coverage (x)	—	-2676.42x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-253.34x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-3008.67x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-14.29x Weak Weak Operating income divided by interest expense Optimal: > 5x	-8.28x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-29.20M	$-26.14M	—	$-455.00K	$-16.58M	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	—	—	$0.03	$0.06	—	—	—
Basic EPS, GAAP (USD)	$-1.67	$-5.65	$-1.28	$-1.20	$-0.86	$-0.27	—
Free Cash Flow per Share (USD)	$-1.97	$-4.28	$-0.75	$-1.04	$-0.50	$-0.17	—
Book Value per Share (USD)	$1.37	$0.65	$-0.11	$-0.03	$1.10	$-0.31	—
Tangible Book Value per Share (USD)	$1.37	$0.65	$-0.11	$-0.03	$1.10	$-0.31	—
Basic Weighted Avg Shares (shares)	15.89M	6.70M	24.54M	15.06M	11.68M	8.50M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$30.02M	$6.83M	$-4.13M	$-640.00K	$16.31M	$-2.67M	—
Total Equity (USD)	$30.20M	$7.43M	$-3.81M	$-466.00K	$16.48M	$-2.67M	$-884.00K

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	$675.00K	$951.00K	—	—	—
Depreciation Expense (USD)	$34.00K	$22.00K	$9.00K	$428.00K	$468.00K	$63.00K	—
Net Income, GAAP (USD)	$-26.55M	$-36.73M	$-30.54M	$-18.06M	$-10.02M	$-2.26M	—
Operating Cash Flow (USD)	$-31.32M	$-28.57M	$-18.28M	$-15.65M	$-5.77M	$-1.46M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Unicycive Therapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare UNCY with peers